NT-proBNP Thresholds for Heart Failure Diagnosis

Introduction to NT-proBNP Thresholds

The European Society of Cardiology recommends using NT-proBNP ≤300 pg/mL to exclude acute heart failure with 99% sensitivity and 98% negative predictive value, and apply age-stratified thresholds to diagnose heart failure with increasing specificity at higher values 1, 2

NT-proBNP ≤300 pg/mL effectively excludes acute heart failure with sensitivity of 99% (95% CI 0.97-1.00) and negative predictive value of 98% (95% CI 0.89-1.0) 3, 2
This threshold is optimal for patients presenting with acute onset or worsening symptoms in emergency settings 1
At this cut-off, only 0-25 false negative diagnoses occur per 1000 patients tested (assuming prevalence of 0.82) 2

NT-proBNP 300-1800 pg/mL indicates possible heart failure requiring confirmatory testing with sensitivity of 90% (95% CI 0.86-0.93) and specificity of 76% (95% CI 0.69-0.82) 3, 2
Patients in this range require echocardiography or cardiac imaging for definitive diagnosis, as specificity remains modest 4, 5

NT-proBNP ≥1800 pg/mL strongly suggests acute heart failure with specificity ranging from 72-95% 3, 2
Only three study cohorts reported data at this threshold, with sensitivity ranging from 67-87% 3
Confirmatory cardiac imaging remains necessary even at this elevated threshold 4, 5

No statistically significant difference exists between BNP and NT-proBNP at rule-out thresholds (p>0.05) 2, 5
BNP ≤100 pg/mL excludes heart failure with 95% sensitivity (95% CI 0.93-0.96) and 94% negative predictive value 3

Do not use NT-proBNP as the sole diagnostic test—always confirm with echocardiography or cardiac imaging, particularly in the intermediate range 4, 5

Obtain baseline pro-BNP at hospital admission to establish severity of decompensation and predict short-term mortality risk, as recommended by the European Society of Cardiology 6, 7
A discharge BNP >250 pg/mL or NT-proBNP >137 ng/L indicates poor prognosis and need for closer follow-up, according to the European Society of Cardiology 6, 7

Pro-BNP-guided therapy in chronic heart failure may reduce mortality, particularly in patients >75 years, as suggested by the European Society of Cardiology 7
Consider periodic measurements (every 3-6 months) in ambulatory patients to guide medication titration, as recommended by the American Heart Association 8

Adjust interpretation for renal function: In patients with GFR <60 mL/min/1.73 m², use higher thresholds (BNP >200-225 ng/L, NT-proBNP >1200 ng/L), as recommended by the European Society of Cardiology 6, 7
Adjust for obesity: Patients with BMI >35 kg/m² have lower pro-BNP levels despite cardiac dysfunction; use lower cut-offs (BNP >55 ng/L), as suggested by the American College of Cardiology 6, 9
Adjust for age: Use age-stratified thresholds for NT-proBNP (>450 ng/L for <50 years, >900 ng/L for 50-75 years, >1800 ng/L for >75 years), as recommended by the European Society of Cardiology 6, 7
Pro-BNP levels are continuous variables: Even mildly elevated levels carry increased risk, and higher values progressively worsen prognosis, as stated by the American Heart Association 8, 6